Pfizer (NYSE: PFE) reported earnings on May 1. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Pfizer met expectations on revenues and beat slightly on earnings per share.

Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped.

Margins dropped across the board.

Revenue details
 Pfizer recorded revenue of $15.41 billion. The 15 analysts polled by S&P Capital IQ hoped for a top line of $15.43 billion on the same basis. GAAP reported sales were 6.6% lower than the prior-year quarter's $16.50 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.58. The 18 earnings estimates compiled by S&P Capital IQ averaged $0.57 per share. GAAP EPS of $0.24 for Q1 were 14% lower than the prior-year quarter's $0.28 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 80.7%, 60 basis points worse than the prior-year quarter. Operating margin was 20.4%, 1,310 basis points worse than the prior-year quarter. Net margin was 11.6%, 190 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $15.52 billion. On the bottom line, the average EPS estimate is $0.56.

Next year's average estimate for revenue is $62.16 billion. The average EPS estimate is $2.26.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,500 members out of 6,092 rating the stock outperform, and 592 members rating it underperform. Among 1,446 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,351 give Pfizer a green thumbs-up, and 95 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.33.

The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Pfizer the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.